Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology
2017/03/08 by Robert S. Fisher, J. Helen Cross, Jacqueline A. French +10 · 56 citations
Medicine · Neuroscience · #Epilepsy research and treatment #Neuroscience and Neuropharmacology Research #Pharmacological Effects and Toxicity Studies
paper · pdf · doi:10.1111/epi.13670
Abstract
The International League Against Epilepsy (ILAE) presents a revised operational classification of seizure types. The purpose of such a revision is to recognize that some seizure types can have either a focal or generalized onset, to allow classification when the onset is unobserved, to include some missing seizure types, and to adopt more transparent names. Because current knowledge is insufficient to form a scientifically based classification, the 2017 Classification is operational (practical) and based on the 1981 Classification, extended in 2010. Changes include the following: (1) "partial" becomes "focal"; (2) awareness is used as a classifier of focal seizures; (3) the terms dyscognitive, simple partial, complex partial, psychic, and secondarily generalized are eliminated; (4) new focal seizure types include automatisms, behavior arrest, hyperkinetic, autonomic, cognitive, and emotional; (5) atonic, clonic, epileptic spasms, myoclonic, and tonic seizures can be of either focal or generalized onset; (6) focal to bilateral tonic-clonic seizure replaces secondarily generalized seizure; (7) new generalized seizure types are absence with eyelid myoclonia, myoclonic absence, myoclonic-atonic, myoclonic-tonic-clonic; and (8) seizures of unknown onset may have features that can still be classified. The new classification does not represent a fundamental change, but allows greater flexibility and transparency in naming seizure types.
Citations
Cited by
- ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology
- Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy
- Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children
- Seizure Frequency Process and Outcome Quality Measures
- Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
- The Human Phenotype Ontology in 2021
- The role of ubiquitin C–terminal hydrolase (UCH‐L1) and protein S100B in differentiating patients with epileptic and psychogenic non‐epileptic seizures – Pilot study
- The role of electroencephalography in epilepsy research—From seizures to interictal activity and comorbidities
- Cenobamate as add‐on treatment for SCN8A developmental and epileptic encephalopathy
- Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study
- Applicability and feasibility of the updated ILAE seizure classification in secondary referral centers
- Early Seizure Recurrence in Patients With Known Epilepsy Presenting to the Emergency Department After a Seizure
- A prospective randomized crossover trial investigating melatonin versus sleep deprivation for sleep induction in nap electroencephalography
- Ketogenic diet for infantile epileptic spasms
- Frontiers in EEG as a tool for the management of pediatric epilepsy: Past, present, and future
- Is highly purified cannabidiol a treatment opportunity for drug‐resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder?
- GABRA2‐related encephalopathy: Identification of two phenotypes with distinctive electroclinical features
- Wearable electroencephalography for ultra-long-term seizure monitoring: a systematic review and future prospects
- Deep learning–based detection of generalized convulsive seizures using a wrist‐worn accelerometer
- Building a dashboard to inform policy and clinical practice using the Irish epilepsy electronic patient record: Towards a learning health system
- Antiseizure medication choice in diffuse glioma: A single‐center population‐based experience
- Epilepsy surgery in Sturge–Weber syndrome with unilateral or bilateral asymmetric brain involvement: Boston Children's Hospital experience
- The epilepsy–autism phenotype associated with developmental and epileptic encephalopathies: New mechanism‐based therapeutic options
- Implementing intraoperative high‐density electrocorticography during epilepsy surgery
- Behavioral Adverse Effects During Initial Six Weeks of Levetiracetam Therapy in Children with Epilepsy: A Prospective Cohort Study
- Association study of ADORA2A gene polymorphisms with adverse drug reactions to valproic acid and oxcarbazepine in the treatment of children with epilepsy
- Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant focal epilepsies treated in the Expanded Access Program
- Neonatal seizures: Advances in diagnosis and management
- WONOEP XVII appraisal: Targeting network excitability beyond the synapse ‐Neurotransmitter, ionic, and electro ‐diffusions
- The impact of revised definitions on the epidemiology of status epilepticus: A population‐based study
- The upside of epilepsy: Theories of an evolutionary paradox
- Defining the phenotypic spectrum of SLC6A1 mutations. [europepmc]
- Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. [europepmc]
- De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias. [europepmc]
- Neurologic phenotypes associated with COL4A1 / 2 mutations: Expanding the spectrum of disease. [europepmc]
- Postconvulsive central apnea as a biomarker for sudden unexpected death in epilepsy (SUDEP). [europepmc]
- Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. [europepmc]
- Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA B R encephalitis. [europepmc]
- Association of Closed-Loop Brain Stimulation Neurophysiological Features With Seizure Control Among Patients With Focal Epilepsy. [europepmc]
- Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. [europepmc]
- A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy. [europepmc]
- GSK-3 β at the Intersection of Neuronal Plasticity and Neurodegeneration. [europepmc]
- Clinical risk factors in SUDEP: A nationwide population-based case-control study. [europepmc]
- Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. [europepmc]
- The postictal state - What do we know? [europepmc]
- Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. [europepmc]
- Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. [europepmc]
- Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures. [europepmc]
- Epileptic seizures. [europepmc]
- A taxonomy of seizure dynamotypes. [europepmc]
- West syndrome: a comprehensive review. [europepmc]
- The Human Phenotype Ontology in 2021. [europepmc]
- The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. [europepmc]
- Cognitive Impairment in People with Epilepsy. [europepmc]
- Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. [europepmc]
- Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. [europepmc]
Related